文献速递艾滋病与性传播感染

复制型仙台病毒载体HIV-1 Gag疫苗鼻内接种的首个人体安全性及免疫原性评估:初免-加强方案诱导强效T细胞或抗体应答

First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens.
PubMed 文献 · J Infect Dis · 2016-10-17

四种初免-加强方案均耐受良好;SeV-Gag初免后Ad35-GRIN加强诱导更高且持久的Gag特异性IFN-γ应答和功能性CD8+ T细胞应答,而Ad35-GRIN初免后SeV-Gag加强诱导最高Gag特异性抗体滴度。

要点

  • 所有初免-加强方案耐受良好,未报告安全性问题。
  • SeV-Gag初免后Ad35-GRIN加强诱导高应答率(96%)和持久T细胞应答。
  • Ad35-GRIN初免后SeV-Gag加强诱导最高Gag特异性抗体滴度。

核心结论

  • SeV-Gag初免可诱导功能性、持久的HIV特异性T细胞应答并增强抗体应答。
  • 初免-加强顺序似乎决定刺激免疫应答的臂别。

研究设计与样本

  • 受试者分配至4种初免-加强方案(0和4个月给药;疫苗与安慰剂比12:4)。

主要发现

  • Gag特异性IFN-γ ELISPOT应答率在SeV-Gag初免后Ad35-GRIN加强组(SLA和SHA)为96%,几何平均应答248 spot-forming units。
  • 单剂Ad35-GRIN后应答率为56%、几何平均54 spot-forming units;单剂SeV-Gag后应答率为55%、几何平均59 spot-forming units。
  • 初免-加强完成后应答持续≥8个月。
  • SLA和SHA组在Ad35-GRIN加强后见功能性CD8+ T细胞应答,病毒抑制试验中广度、幅度和频率更大。
  • SeV-Gag未在ASH组增强T细胞计数;最高Gag特异性抗体滴度见于ASH组;黏膜抗体应答偶发。

临床怎么用

  • 鼻内复制型SeV载体HIV疫苗初免可诱导持久T细胞免疫,初免-加强顺序可设计以偏向T细胞或抗体应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We report the first-in-human safety and immunogenicity assessment of a prototype intranasally administered, replication-competent Sendai virus (SeV)-vectored, human immunodeficiency virus type 1 (HIV-1) vaccine. METHODS: Sixty-five HIV-1-uninfected adults in Kenya, Rwanda, and the United Kingdom were assigned to receive 1 of 4 prime-boost regimens (administered at 0 and 4 months, respectively; ratio of vaccine to placebo recipients, 12:4): priming with a lower-dose SeV-Gag given intranasally, followed by boosting with an adenovirus 35-vectored vaccine encoding HIV-1 Gag, reverse transcriptase, integrase, and Nef (Ad35-GRIN) given intramuscularly (SLA); priming with a higher-dose SeV-Gag given intranasally, followed by boosting with Ad35-GRIN given intramuscularly (SHA); priming with Ad35-GRIN given intramuscularly, followed by boosting with a higher-dose SeV-Gag given intranasally (ASH); and priming and boosting with a higher-dose SeV-Gag given intranasally (SHSH). RESULTS: All vaccine regimens were well tolerated. Gag-specific IFN-γ enzyme-linked immunospot-determined response rates and geometric mean responses were higher (96% and 248 spot-forming units, respectively) in groups primed with SeV-Gag and boosted with Ad35-GRIN (SLA and SHA) than those after a single dose of Ad35-GRIN (56% and 54 spot-forming units, respectively) or SeV-Gag (55% and 59 spot-forming units, respectively); responses persisted for ≥8 months after completion of the prime-boost regimen. Functional CD8+ T-cell responses with greater breadth, magnitude, and frequency in a viral inhibition assay were also seen in the SLA and SHA groups after Ad35-GRIN boost, compared with those who received either vaccine alone. SeV-Gag did not boost T-cell counts in the ASH group. In contrast, the highest Gag-specific antibody titers were seen in the ASH group. Mucosal antibody responses were sporadic. CONCLUSIONS: SeV-Gag primed functional, durable HIV-specific T-cell responses and boosted antibody responses. The prime-boost sequence appears to determine which arm of the immune response is stimulated. CLINICAL TRIALS REGISTRATION: NCT01705990.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Nyombayire J, Anzala O, Gazzard B, et al. First-in-Human Evaluation of the Safety and Immunogenicity of an Intranasally Administered Replication-Competent Sendai Virus-Vectored HIV Type 1 Gag Vaccine: Induction of Potent T-Cell or Antibody Responses in Prime-Boost Regimens. J Infect Dis. 2016. PMID: 28077588. doi:10.1093/infdis/jiw500

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。